Observational analysis demonstrates that isorhamnetin-3-O-neohespeidoside reduces melanin in B16 melanoma, implying its dual inhibitory effects on tyrosinase and MC1R.
Key Points
Isorhamnetin-3-O-neohespeidoside reduced MC1R expression by 33.39% in B16 melanoma cells.
Inhibition of tyrosinase activity was observed at 44.42%, with statistical significance p < 0.0001.
The compound decreased melanin content by 38.7% and enhanced autophagy indicated by LC3-II upregulation.
Integrated computational and experimental approaches allow for identifying multi-target depigmenting agents.